Overview

Long-term Safety and Tolerability of TRI476 (Oxcarbazepine) in Children With Inadequately Controlled Partial Onset Seizures

Status:
Completed
Trial end date:
2019-09-30
Target enrollment:
Participant gender:
Summary
This study is designed to provide long term safety data of TRI476 in children with inadequately-controlled partial seizures. This study is conducted in patients who complete the core study CTRI476B1301. Blinding is maintained during the transition and dose adjustment phase of the extension study. All patients are treated with TRI476 from the dose adjustment phase onwards. The purpose of study is to confirm that TRI476 as adjunctive therapy is safe.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Nobelpharma
Novartis Pharmaceuticals
Treatments:
Carbamazepine
Oxcarbazepine